Arachidonic acid pathway corticosteroids

ACC1 is strictly cytosolic and is enriched in liver, adipose tissue and lactating mammary tissue. ACC2 was originally discovered in rat heart but is also expressed in liver and skeletal muscle. ACC2 has an N -terminal extension that contains a mitochondrial targeting motif and is found associated with carnitine palmitoyltransferase I (CPT I) allowing for rapid regulation of CPT I by the malonyl-CoA produced by ACC. Both isoforms of ACC are allosterically activated by citrate and inhibited by palmitoyl-CoA and other short- and long-chain fatty acyl-CoAs. Citrate triggers the polymerization of ACC1 which leads to significant increases in its activity. Although ACC2 does not undergo significant polymerization (presumably due to its mitochondrial association) it is allosterically activated by citrate. Glutamate and other dicarboxylic acids can also allosterically activate both ACC isoforms.

1. Metabolism
     Global/overview    Carbohydrate    Energy    Lipid    Nucleotide    Amino acid    Other amino    Glycan
     Cofactor/vitamin    Terpenoid/PK    Other secondary metabolite    Xenobiotics    Chemical structure
2. Genetic Information Processing
3. Environmental Information Processing
4. Cellular Processes
5. Organismal Systems
6. Human Diseases
7. Drug Development

Details about the active site feature of lipoxygenase were revealed in the structure of porcine leukocyte 12-lipoxygenase catalytic domain complex [22] [24] In the 3D structure, the substrate analog inhibitor occupied a U-shaped channel open adjacent to the iron site. This channel could accommodate arachidonic acid without much computation, defining the substrate binding details for the lipoxygenase reaction. In addition, a plausible access channel, which intercepts the substrate binding channel and extended to the protein surface could be counted for the oxygen path.

Although less effective in lowering LDL levels, the ability of fibrates to increase HDL and lower triglyceride levels seems to reduce insulin resistance when the dyslipidemia is associated with other features of the metabolic syndrome ( hypertension and diabetes mellitus type 2 ). [4] They are therefore used in many hyperlipidemias . Due to a rare paradoxical decrease in HDL-C seen in some patients on fenofibrate, as per US FDA label change, it is recommended that the HDL-C levels be checked within the first few months after initiation of fibrate therapy. If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline. Medwatch

Arachidonic acid pathway corticosteroids

arachidonic acid pathway corticosteroids

Although less effective in lowering LDL levels, the ability of fibrates to increase HDL and lower triglyceride levels seems to reduce insulin resistance when the dyslipidemia is associated with other features of the metabolic syndrome ( hypertension and diabetes mellitus type 2 ). [4] They are therefore used in many hyperlipidemias . Due to a rare paradoxical decrease in HDL-C seen in some patients on fenofibrate, as per US FDA label change, it is recommended that the HDL-C levels be checked within the first few months after initiation of fibrate therapy. If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline. Medwatch

Media:

arachidonic acid pathway corticosteroidsarachidonic acid pathway corticosteroidsarachidonic acid pathway corticosteroidsarachidonic acid pathway corticosteroidsarachidonic acid pathway corticosteroids